A2 Vertaisarvioitu katsausartikkeli tieteellisessä lehdessä
Severe bronchiolitis profiling as the first step towards prevention of asthma
Tekijät: Orzołek Izabela, Ambrożej Dominika, Makrinioti Heidi, Zhu Zhaozhong, Jartti Tuomas, Feleszko Wojciech
Julkaisuvuosi: 2023
Journal: Allergologia et Immunopathologia
Tietokannassa oleva lehden nimi: Allergologia et immunopathologia
Lehden akronyymi: Allergol Immunopathol (Madr)
Vuosikerta: 51
Numero: 3
Aloitussivu: 99
Lopetussivu: 107
ISSN: 0301-0546
eISSN: 1578-1267
DOI: https://doi.org/10.15586/aei.v51i3.788
Verkko-osoite: https://doi.org/10.15586/aei.v51i3.788
Rinnakkaistallenteen osoite: https://research.utu.fi/converis/portal/detail/Publication/179851410
Bronchiolitis is the most common respiratory infection leading to hospitalization and constitutes a significant healthcare burden. The two main viral agents causing bronchiolitis, respiratory syncytial virus (RSV) and rhinovirus (RV), have distinct cytopathic, immune response, and clinical characteristics. Different approaches have been suggested for subtyping bronchiolitis based on viral etiology, atopic status, transcriptome profiles in blood, airway metabolome, lipidomic data, and airway microbiota. The highest risk of asthma at school age has been in a subgroup of bronchiolitis characterized by older age, high prevalence of RV infection, previous breathing problems, and/or eczema. Regarding solely viral etiology, RV-bronchiolitis in infancy has been linked to a nearly three times higher risk of developing asthma than RSV-bronchiolitis. Although treatment with betamimetics and systemic corticosteroids has been found ineffective in bronchiolitis overall, it can be beneficial for infants with severe RV bronchiolitis. Thus, there is a need to develop a more individualized therapeutic approach for bronchiolitis and follow-up strategies for infants at higher risk of asthma in the future perspective.
Ladattava julkaisu This is an electronic reprint of the original article. |  |
